Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NXTC – Nextcure Inc

NextCure, Inc.
NXTC
$0.4485
Name : NextCure, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $12,580,515.00
EPSttm : -1.77
finviz dynamic chart for NXTC
NextCure, Inc.
$0.4485
3.27%
$0.0142

Float Short %

0.84

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.01

EPS Last/This Y

0.4

EPS This/Next Y

0.16

Price

0.45

Target Price

3

Analyst Recom

1

Performance Q

-40.44

Relative Volume

0.52

Beta

1.03

Ticker: NXTC




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-04-14NXTC0.320.000.0046
2025-04-15NXTC0.33010.000.0047
2025-04-16NXTC0.32240.000.0047
2025-04-17NXTC0.35190.000.0047
2025-04-18NXTC0.36120.000.0047
2025-04-21NXTC0.37580.000.0047
2025-04-22NXTC0.3910.000.0037
2025-04-23NXTC0.42750.000.0037
2025-04-24NXTC0.38370.000.0038
2025-04-25NXTC0.460038
2025-04-28NXTC0.46480038
2025-04-29NXTC0.48330.000.0039
2025-04-30NXTC0.47050.000.0039
2025-05-01NXTC0.470.000.0039
2025-05-02NXTC0.46170.000.0039
2025-05-05NXTC0.44990.000.0039
2025-05-06NXTC0.430.000.0040
2025-05-07NXTC0.3510.000.0040
2025-05-08NXTC0.38640.000.0040
2025-05-09NXTC0.41640.000.0040
2025-05-12NXTC0.41010.000.0040
2025-05-13NXTC0.44390.000.0041
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-04-14NXTC0.3123.4- -1.75
2025-04-15NXTC0.3323.4- -1.75
2025-04-16NXTC0.3423.4- -1.75
2025-04-17NXTC0.3623.4- -1.75
2025-04-18NXTC0.3623.4- -1.75
2025-04-21NXTC0.3923.4- -1.75
2025-04-22NXTC0.4023.4- -1.75
2025-04-23NXTC0.4223.4- -1.75
2025-04-24NXTC0.4023.4- -1.75
2025-04-25NXTC0.4623.4- -1.75
2025-04-28NXTC0.4623.4- -1.75
2025-04-29NXTC0.4923.4- -1.75
2025-04-30NXTC0.4723.4- -1.75
2025-05-01NXTC0.4823.4- -1.75
2025-05-02NXTC0.4423.4- -1.75
2025-05-05NXTC0.4522.7- -1.75
2025-05-06NXTC0.4122.7- -1.75
2025-05-07NXTC0.3822.7- -1.75
2025-05-08NXTC0.3822.7- -1.75
2025-05-09NXTC0.4522.7- -1.58
2025-05-12NXTC0.4322.7- -1.58
2025-05-13NXTC0.4530.0- -1.58
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-04-14NXTC0.00-15.240.27
2025-04-15NXTC0.00-15.240.27
2025-04-16NXTC0.00-15.240.27
2025-04-17NXTC0.00-15.240.27
2025-04-18NXTC0.00-15.240.27
2025-04-21NXTC0.00-15.750.27
2025-04-22NXTC0.00-15.750.27
2025-04-23NXTC0.00-15.750.27
2025-04-24NXTC0.00-15.750.27
2025-04-25NXTC0.00-15.750.27
2025-04-28NXTC0.00-15.900.16
2025-04-29NXTC0.00-15.900.16
2025-04-30NXTC0.00-15.900.16
2025-05-01NXTC0.00-15.900.16
2025-05-02NXTC0.00-15.900.16
2025-05-05NXTC0.00-15.920.16
2025-05-06NXTC0.00-15.920.16
2025-05-07NXTC0.00-15.920.16
2025-05-08NXTC0.00-15.920.16
2025-05-09NXTC0.00-15.920.16
2025-05-12NXTC0.00-21.220.84
2025-05-13NXTC0.00-21.220.84
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.39

Avg. EPS Est. Current Quarter

-0.39

Avg. EPS Est. Next Quarter

-0.39

Insider Transactions

Institutional Transactions

-21.22

Beta

1.03

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

6

Growth Score

21

Sentiment Score

51

Actual DrawDown %

98.8

Max Drawdown 5-Year %

-99.3

Target Price

3

P/E

Forward P/E

PEG

P/S

P/B

0.22

P/Free Cash Flow

EPS

-1.77

Average EPS Est. Cur. Y​

-1.58

EPS Next Y. (Est.)

-1.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.52

Return on Equity vs Sector %

-112.4

Return on Equity vs Industry %

-95.4

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.16

EBIT Estimation

NextCure, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 43
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading